SCHEMBL6630941

SCHEMBL6630941

CCC(C(=O)O)(C(=O)O)C(CC(=O)O)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.37
HSPD1 P10809 1/20 0.36
BLM P54132 1/20 0.36
HSPE1 P61604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
THRB P10828 1/20 0.32
KMT2A Q03164 1/20 0.32
FFAR3 O14843 1/20 0.32
GPR84 Q9NQS5 4/20 0.31
FOLH1 Q04609 1/20 0.31
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11340349 0.80 TDP1 (0.44) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL6631030 0.78 CYP1A2 (0.38) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL8968596 0.77 HSPD1 (0.47) TDP1HSPD1BLMHSPE1SLC22A6
SCHEMBL3884302 0.76 TDP1 (0.39) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL14620834 0.76 TDP1 (0.39) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL17376894 0.72 TDP1 (0.36) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL27368103 0.72 TDP1 (0.36) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL6789228 0.72 HSPD1 (0.32) HSPD1BLMHSPE1
SCHEMBL8853350 0.72 TDP1 (0.43) TDP1HSPD1BLMHSPE1SMN1; SMN2
SCHEMBL1941442 0.72 TDP1 (0.43) TDP1HSPD1BLMHSPE1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
EP-3508474-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR Pharmaceuticals Co., Ltd. (JP) 2019-07-10 EP disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed
US-20040231558-A1 Has a clear hue, high light fastness and high moisture resistance MITSUI CHEMICALS, INC. (JP) 2004-11-25 US disclosed
EP-1441013-A1 WATERCOLOR INK Mitsui Chemicals, Inc. (JP) 2004-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 TDP1 3697/4885HSPD1 94/4885BLM 4815/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 TDP1 2736/4885HSPD1 106/4885BLM 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.